{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:29Z","timestamp":1791912509938,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This phase 3b, open\u2010label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3\u2009cycles of 4 once\u2010weekly infusions, with 4\u2009weeks between cycles) or a cycle followed by every\u2010other\u2010week (Q2W) dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult participants with anti\u2010acetylcholine receptor antibody\u2010positive generalized myasthenia gravis (gMG) were randomized 3:1 to Q2W or fixed cycles dosing of efgartigimod (10\u2009mg\/kg intravenously) for 21\u2009weeks. The primary endpoint was the mean change from baseline in total Myasthenia Gravis Activities of Daily Living (MG\u2010ADL) score averaged across 21\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty\u2010nine participants were treated (fixed cycles,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917; Q2W,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952). Least squares (LS) mean (95% CI) of the change from baseline in MG\u2010ADL total score from Weeks 1 to 21 was \u22125.1 (\u22126.5 to \u22123.8) in the fixed cycles arm and \u22124.6 (\u22125.4 to \u22123.8) in the Q2W arm. Clinical improvements were observed in MG\u2010ADL total scores as early as Week 1 and were maintained throughout the study. Achievement of minimal symptom expression (MG\u2010ADL: 0\u20131) from Weeks 1 to 21 occurred in 47.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098\/17) and 44.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923\/52) of participants in the fixed cycles and Q2W arms, respectively. Efgartigimod was well tolerated; COVID\u201019, headache, and upper respiratory tract infection were the most common treatment\u2010emergent adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Efgartigimod administered as either fixed cycles or Q2W dosing results in rapid, robust, and sustained clinically meaningful improvement. These results build upon previous studies and provide additional efgartigimod dosing approaches to achieve and sustain clinical efficacy in patients with gMG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70051","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T03:46:26Z","timestamp":1744602386000},"page":"1162-1170","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["<scp>ADAPT NXT<\/scp>\n                    : Fixed Cycles or Every\u2010Other\u2010Week\n                    <scp>IV<\/scp>\n                    Efgartigimod in Generalized Myasthenia Gravis"],"prefix":"10.1002","volume":"12","author":[{"given":"Ali A.","family":"Habib","sequence":"first","affiliation":[{"name":"Department of Neurology University of California, Irvine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G.","family":"Claeys","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospitals Leuven  Leuven Belgium"},{"name":"Laboratory for Muscle Diseases and Neuropathies KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Ellen &amp; Martin Prosserman Centre for Neuromuscular Diseases University Health Network  Toronto Ontario Canada"},{"name":"University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yessar","family":"Hussain","sequence":"additional","affiliation":[{"name":"Austin Neuromuscular Center  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gwathmey","sequence":"additional","affiliation":[{"name":"Department of Neurology Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sahagian","sequence":"additional","affiliation":[{"name":"The Neurology Center of Southern California  Carlsbad California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-1072","authenticated-orcid":false,"given":"Elena","family":"Cort\u00e9s\u2010Vicente","sequence":"additional","affiliation":[{"name":"Neuromuscular Diseases Unit, Department of Neurology Hospital de la Santa Creu i Sant Pau  Barcelona Spain"},{"name":"Biomedical Research Institute Sant Pau  Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras, CIBERER  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sumbul","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa H.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hristova","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Masschaele","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"Emeritus Fondazione IRCCS Istituto Neurologico Carlo Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Neurology With Experimental Neurology and NeuroScience Clinical Research Center Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-4694","authenticated-orcid":false,"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[{"name":"Reference Center for Neuromuscular Disorders and ALS Timone Hospital University  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ADAPT NXT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010019\u20100079\u2010y"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2019.01121"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118074"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00981"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27832"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0318-6"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00159\u20109"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2122710"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.07.007"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.05.023"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176166"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2025.2459934"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z"},{"key":"e_1_2_9_32_1","unstructured":"\u201cVYVGART HYTRULO. Prescribing Information. argenx \u201d2024 https:\/\/www.argenx.com\/product\/vyvgart\u2010hytrulo\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27448"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"key":"e_1_2_9_36_1","unstructured":"J. F.Howard Jr. H.Murai S.Muppidi et\u00a0al. \u201cAchievement of Minimal Symptom Expression in Acetylcholine Receptor Antibody Positive Participants With Generalized Myasthenia Gravis in ADAPT\/ADAPT+ Studies Resulted in Substantial Improvement in Disease Specific Measures \u201dOral Presentation at: Myasthenia Gravis Foundation of America (MGFA) Scientific Session at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; November 2023; Phoenix AZ USA."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28334"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12293-5"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27974"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28003"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1936500"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010021\u201000285\u2010w"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T09:02:24Z","timestamp":1750150944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/acn3.70051"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70051","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"2024-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}